Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study코로나19 중증 환자에 대한 토실리주맙 치료: 후향적 관찰 연구Observational Study Published on 2021-04-012022-09-12 Journal: International Journal of Infectious Diseases [Category] SARS, 임상, 진단, 치료법, [키워드] acute respiratory distress syndrome administration attenuate chimeric antigen receptor conducted COVID-19 COVID-19 patients Critically ill Critically ill patient Cytokine release syndrome Cytokine storm death disease severity distress dysregulated immune response group hospital hospital discharge intensive care interleukin-6 receptor Intubated invasive measurement mechanical ventilation not different on mechanical ventilation outcome Patient patients patients treated percentage Pneumonia pro-inflammatory cytokine progressed required Respiratory disease retrospective SARS-CoV2 Secondary infection severe COVID-19 infections subgroup of patient Tocilizumab treat Treatment venous [DOI] 10.1016/j.ijid.2021.02.057 PMC 바로가기 [Article Type] Observational Study
Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case reportCOVID-19 ARDS 환자에서 토실리주맙 치료 후 침습성 폐 아스페르길루스증: 증례 보고Case Reports Published on 2021-04-012022-09-11 Journal: Diagnostic microbiology and infectious disease [Category] SARS, 진단, 치료법, 치료제, [키워드] aspergillosis Case report coronavirus coronavirus disease coronavirus disease-2019 COVID-19 Critically ill Critically ill patient critically ill patients fungal fungal infections immune interleukin-6 interleukin-6 receptor invasive Invasive pulmonary aspergillosis modulating opportunistic infection opportunistic Infections patient with COVID-19 pulmonary aspergillosis pulmonary disease receptor antagonist therapy Tocilizumab treat treatment with tocilizumab [DOI] 10.1016/j.diagmicrobio.2020.115272 PMC 바로가기 [Article Type] Case Reports
Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety입원한 코로나19 환자의 토실리주맙: 임상 결과, 염증 마커 동역학 및 안전성Observational Study Published on 2021-04-012022-09-11 Journal: Journal of medical virology [Category] MERS, SARS, 임상, 진단, 치료기술, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted hazard ratio baseline benefit C-reactive protein cause clinical Clinical improvement Comorbidity conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Cox proportional-hazards model cytopenias defined detect discharge evaluated fibrinogen hospitalized patient hospitalized patients immunomodulatory IMPROVE Infection Inflammation Inflammatory interleukin-6 interleukin-6 receptor marker morbidity Mortality Ordinal Scale outcome outcomes oxygen Oxygen requirements Patient Probability proportion receive receiving receptor antagonist reduced reduction in requiring supplemental oxygen respiratory Retrospective study SARS-CoV-2 severe acute respiratory syndrome Coronavirus severity subsequent infections supplemental oxygen survival temperature Tocilizumab transaminitis Treatment University of Washington Weighting with COVID-19 [DOI] 10.1002/jmv.26674 PMC 바로가기 [Article Type] Observational Study
Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumabCOVID-19의 대사체/지질체 프로파일링 및 토실리주맙에 대한 개별 반응Research Article Published on 2021-02-012022-08-13 Journal: PLoS Pathogens [Category] Biochemistry, MERS, 진단, [키워드] absence Accuracy acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 affecting age age- and sex-matched controls alteration Analysis analyzed approach biochemical caused change changes in characterized Clinical data clinical manifestations Clinical symptoms Control control group controls coronavirus disease Coronavirus-2 correlation correlations COVID-19 COVID-19 pandemic COVID-19 patient COVID-19 patients determinant EDTA evaluated First wave Florence form global health Health heterogeneity humanized monoclonal antibody induce Infection intensive care treatment interleukin-6 interleukin-6 receptor Italy Magnetic resonance spectroscopy metabolite metabolome metabolomic metabolomics MONITOR NMR-based metabolomic and lipidomic profiling Novel coronavirus novel coronavirus disease nuclear nuclear magnetic resonance open outcomes pandemic pathophysiological mechanism Patient patients patients hospitalized plasma plasma-EDTA sample plasma-EDTA samples provide recombinant humanized monoclonal antibody respiratory response to treatment SARS-CoV-2 SARS-COV-2 infection Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 small-molecule profile subset Symptom the disease Tocilizumab tocilizumab administration Treatment treatment with tocilizumab world population [DOI] 10.1371/journal.ppat.1009243 PMC 바로가기 [Article Type] Research Article
Tocilizumab in the Management of COVID-19: A Preliminary ReportCOVID-19 관리에서 Tocilizumab: 예비 보고서Observational Study Published on 2021-02-012022-09-12 Journal: The American journal of the medical sciences [Category] MERS, 임상, 진단, [키워드] acute respiratory distress Administered administration Admission age analyzed association average benefit Care collected Confirmed COVID-19 death evaluate hospital hospitalized patient ICU ICU admission IL-6 increased mortality intensive care interleukin-6 receptor likelihood mechanical ventilation monoclonal antibody Mortality Odds ratio off-label outcome outcomes overall mortality Patient patients with COVID-19 Philadelphia Pneumonia progression Prospective report Respiratory failure Retrospective analysis subject suggested syndrome Treatment Trial with COVID-19 [DOI] 10.1016/j.amjms.2020.11.005 PMC 바로가기 [Article Type] Observational Study
On the role of bacterial metalloproteases in COVID-19 associated cytokine stormHypothesis Published on 2021-01-132022-10-31 Journal: Cell Communication and Signaling : CCS [Category] COVID-19, MERS, [키워드] Abstract Bacteria Bacterial Cell Co-infection COVID-19 Critical Cytokine release syndrome Cytokine storm Cytokine storms decrease ENhance Express expressed gp130 Hypothesis hypothesise IL-6 IL-6Rα induce Infection Inflammatory response interleukin-6 receptor Listeria monocytogene mechanism membrane membrane-bound Metalloprotease mortality rate Multiorgan organ Prophylactic Pseudomonas aeruginosa receptors reducing shedding sIL-6R Staphylococcus aureus Support trans-signaling use of antibiotics validation viral infections Viral pneumonia [DOI] 10.1186/s12964-020-00699-3 PMC 바로가기 [Article Type] Hypothesis
“Say Ninetynine”: It’s Never too Late to Recover from COVID-19"Say Ninetynine": COVID-19에서 회복하기에 너무 늦은 때는 없습니다.Case Reports Published on 2021-01-012022-09-12 Journal: The Journal of Frailty & Aging [Category] 진단, [키워드] acute respiratory syndrome Administered age aging Anticoagulant approach caused Clinical improvement Comprehensive comprehensive geriatric assesment coronavirus COVID-19 develop effective Efficacy frailty Hydroxychloroquine Infection interleukin-6 receptor intravenous male monoclonal antibodies monoclonal antibody Older Respiratory failure SARS-CoV-2 severity the disease therapeutic approaches therapy Treatment [DOI] 10.14283/jfa.2020.41 PMC 바로가기 [Article Type] Case Reports
Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study중증 COVID-19 환자를 위한 Tocilizumab: 후향적, 다기관 연구Multicenter Study Published on 2021-01-012022-09-12 Journal: Expert review of anti-infective therapy [Category] MERS, 진단, [키워드] 24 hour age C-reactive protein change changes in clinical clinical status Concentration COVID-19 decrease dose Evidence fibrinogen Final IMPROVE inflammatory markers Inflammatory response inhibitor interleukin-6 interleukin-6 receptor male Oxygen therapy Patient patients patients died Poland procalcitonin reducing retrospective Retrospective study SARS-CoV-2 serum Seven severe coronavirus disease severe COVID-19 significantly Symptom symptom onset therapy Tocilizumab [DOI] 10.1080/14787210.2020.1800453 PMC 바로가기 [Article Type] Multicenter Study
Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia중증 SARS-CoV2 폐렴에서 토실리주맙의 동정적 사용Article Published on 2021-01-012022-09-11 Journal: International Journal of Infectious Diseases [Category] MERS, SARS, 신약개발, 진단, [키워드] acute respiratory distress acute respiratory distress syndrome Administered administration age analyzed ARDS benefit C-reactive protein compassionate-use COVID-19 CRS cytokine Cytokine release syndrome D-dimer death dose drug Evolution Factor FiO2 high oxygen support High-sensitivity C-reactive protein Hospitalized hsCRP IL-6 intensive care interleukin-6 interleukin-6 receptor intravenous Intubated intubation Lymphocytes male Older age oxygen oxygen support Patient patients Pneumonia primary endpoint Prognostic factors receiving receptor antagonist required respiratory distress SARS-CoV-2 SARS-CoV-2 pneumonia SARS-CoV2 saturation severe disease severe SARS severe SARS-CoV-2 significantly syndrome TCZ Tocilizumab Treatment [DOI] 10.1016/j.ijid.2020.10.045 PMC 바로가기 [Article Type] Article
Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19피하 토실리주맙을 사용한 인터루킨-6 수용체 차단은 COVID-19 환자의 응고 활성을 개선합니다Article Published on 2021-01-012022-09-12 Journal: European journal of internal medicine [Category] 진단, [키워드] 95% confidence interval 95%CI activate activated Admission age Analysis Anticoagulants blockade Blood coagulation C-reactive protein change Coagulation Coagulation parameters contribute COVID-19 COVID-19 pathogenesis COVID-19 patient Critical cytokine D-dimer level death develop dose enrolled evaluate the effect fibrinogen humanized monoclonal antibody hypercoagulable hyperinflammation Hyperinflammatory IMPROVE increase in Inflammation interleukin-6 interleukin-6 receptor interquartile range laboratory-confirmed moderate occurred Occurrence parameter Patient patients with COVID-19 Platelet Pneumonia Prophylactic Prophylaxis Prothrombin time receiving receptor reduction reduction in Respiratory function Standard of care Subcutaneous subcutaneous dose sustained therapeutic thromboembolic complications Thromboprophylaxis thrombosis Tocilizumab Treatment were measured [DOI] 10.1016/j.ejim.2020.10.020 PMC 바로가기 [Article Type] Article